SCHEMBL30163238

SCHEMBL30163238

CC(C)(C)OC(=O)Cc1c(-c2ccnc(C#N)c2)ccc2c1CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 7/20 0.54
MYC P01106 1/20 0.35
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
XDH P47989 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
TSHR P16473 1/20 0.32
POLB P06746 1/20 0.32
GLA P06280 1/20 0.32
PARP1 P09874 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
CGAS Q8N884 1/20 0.31
LNPEP Q9UIQ6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22802381 1.00 NLRP3 (0.54) NLRP3MYCALDH1A1KDM4EMEN1
SCHEMBL29691325 0.85 NLRP3 (0.42) NLRP3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL23012413 0.85 NLRP3 (0.42) NLRP3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL29757351 0.85 NLRP3 (0.42) NLRP3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL22802360 0.85 NLRP3 (0.59) NLRP3MYCALDH1A1XDHSLC22A12
SCHEMBL22802385 0.84 NLRP3 (0.55) NLRP3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL29492920 0.84 NLRP3 (0.55) NLRP3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL22867121 0.84 NLRP3 (0.40) NLRP3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL22802375 0.84 NLRP3 (0.59) NLRP3MYCXDHSLC22A12CGAS
Trifluoroacetic Acid SCHEMBL30163273 0.82 NLRP3 (0.55) NLRP3MYCXDHSLC22A12CGAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030879-B2 Sulfonyl acetamides as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2024-07-09 US disclosed
US-11884645-B2 Sulfonyl acetamides as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2024-01-30 US disclosed
US-11834433-B2 Compounds INFLAZOME LIMITED (IE) 2023-12-05 US disclosed
US-11530200-B2 Compounds INFLAZOME LIMITED (IE) 2022-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030879-B2 Sulfonyl acetamides as NLRP3 inhibitors NLRP3, NOD1, NLRP1 NLRP3 1/4885MYC 4225/4885ALDH1A1 1078/4885
US-11884645-B2 Sulfonyl acetamides as NLRP3 inhibitors NLRP3, NOD1, ABCC5 NLRP3 1/4885MYC 4177/4885ALDH1A1 966/4885
US-11834433-B2 Compounds NLRP3, NOD1, PYCARD NLRP3 1/4885MYC 2519/4885ALDH1A1 378/4885
US-11530200-B2 Compounds NLRP3, NOD1, NLRP1 NLRP3 1/4885MYC 2959/4885ALDH1A1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.